Prudential Financial
VTGN icon

Prudential Financial’s VistaGen Therapeutics VTGN Stock Holding History

Prudential Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.3K Buy
+53,100
New +$32.3K ﹤0.01% 2362
2023
Q2 		– Sell
-336
Closed -$1.25K – 2718
2023
Q1 		$1.25K Hold
336
– – ﹤0.01% 2598
2022
Q4 		$1.04K Hold
336
– – ﹤0.01% 2590
2022
Q3 		$2K Hold
336
– – ﹤0.01% 2645
2022
Q2 		$9K Hold
336
– – ﹤0.01% 2654
2022
Q1 		$12K Hold
336
– – ﹤0.01% 2592
2021
Q4 		$20K Sell
336
-43
-11% -$2.8K ﹤0.01% 2613
2021
Q3 		$31K Sell
379
-39
-9% -$3.39K ﹤0.01% 2567
2021
Q2 		$39K Buy
+418
New +$31K ﹤0.01% 2527

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prudential Financial's VTGN Position: Q1 2026 in Review

Prudential Financial opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 53,100 shares worth $30.3K. The stake represents ﹤0.01% of the portfolio and ranks #2362 among its holdings. This is a return to the name: Prudential Financial previously reported a position in VTGN as recently as Q1 2023.

Prudential Financial first reported a position in VTGN in Q2 2021 and has held it in 9 quarters since. The position peaked at $39K in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Prudential Financial held 53,100 shares of VistaGen Therapeutics worth $30.3K as of Q1 2026.
  • VistaGen Therapeutics was a new Prudential Financial position in Q1 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2362 holding.
  • Prudential Financial first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • Prudential Financial's VistaGen Therapeutics position peaked at $39K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.